CVS Health Beats Q4 Results, Cuts Guidance
CVS Health Beats Q4 Results, Cuts Guidance

CVS Health Beats Q4 Results, Cuts Guidance

Feb. 8, 2024, 3:20 p.m., readers: 15

CVS Health (NYSE:CVS) disclosed its fourth-quarter financial results and revised its earnings forecast for 2024 downwards. In the fourth quarter of 2023, CVS Health announced an earnings per share (EPS) of $2.12, surpassing the analysts' consensus of $1.98. The company's revenue for the quarter was $93.81 billion, exceeding expectations of $90.25 billion. Revenue from health services reached $49.15 billion, outperforming the anticipated $45.96 billion by analysts. Looking into the full fiscal year of 2024, CVS Health adjusted its EPS forecast to a minimum of $8.30, a decrease from the previously projected $8.50. This adjustment comes in below the analyst consensus of $8.47.


About NYSE: CVS

C VS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Its Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services.

Price: 77.19
Market cap: 97.1 billion USD
Eps: 6.47
P/e ratio: 11.93
Terminal Research: CVS